SC 13G/A: NOVAVAX INC

AI Summary

SC 13G/A filing by NOVAVAX INC.

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.01 — me of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti

Filing Documents

• d841044dsc13ga.htm (SC 13G/A) — 73KB
• d841044dex991.htm (EX-99.1) — 6KB
• 0001193125-24-164331.txt ( ) — 80KB

From the Filing

SC 13G/A 1 d841044dsc13ga.htm SCHEDULE 13G, AMENDMENT NO. 1 SCHEDULE 13G, AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 Exit Filing)* NOVAVAX, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 670002401 (CUSIP Number) May 10, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). S CHEDULE 13G 1 NAME OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS SK bioscience Co., Ltd. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Korea NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 6,500,000 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 6,500,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,500,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.6% (1)(2) 12 TYPE OF REPORTING PERSON OO (1) The percentages reported in this Amendment are calculated based on (i) 140,403,554 shares of Common Stock outstanding as of April 30, 2024 as set forth in the Issuers Form 10-Q as filed with the Securities and Exchange Commission on May 10, 2024 and (ii) 6,500,000 shares of Common Stock issued to SK bioscience Co., Ltd. pursuant to a securities subscription agreement dated August 8, 2023. (2) See Item 4 below. This constitutes an exit filing for the Reporting Person. Page 2 of 9 Pages S CHEDULE 13G 1 NAME OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS SK chemicals Co., Ltd. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Korea NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 6,500,000 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 6,500,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,500,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.6% (1) 12 TYPE OF REPORTING PERSON OO (1) See Item 4 below. This constitutes an exit filing for the Reporting Person. Page 3 of 9 Pages S CHEDULE 13G 1 NAME OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS SK discovery Co., Ltd. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Korea NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 6,500,000 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 6,500,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,500,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.6% (1) 12 TYPE OF REPORTING PERSON OO (1) See Item 4 below. This constitutes an exit filing for the Reporting Person. Page 4 of 9 Pages S CHEDULE 13G Explanatory Note : This Amendment is being filed to report that the Reporting Persons have ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock of the Issuer. This Amendment constitutes an exit filing for the Reporting Persons. Item1. (a) Name of Issuer: Novavax, Inc. (b) Address of Issuers Principal Executive Offices: 21 Firstfield Road, Gaithersburg, MD 20878. Item2. (a) Name of Persons Filing: SK bioscience Co., Ltd. SK chemicals Co., Ltd. SK discovery Co., Ltd. (b) Address of Principal Business Office or, if none, Residence: For all Reporting Persons, the address is 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13494, Republic of Korea. (c) Citizenship: Each of the Reporting Persons is a company incorporated in the Republic of Korea. (d) Title of Class of Securities: Common stock, par value $0.01 per share (

View Full Filing

View this SC 13G/A filing on SEC EDGAR